Cargando…

Cnp Promoter-Driven Sustained ERK1/2 Activation Increases B-Cell Activation and Suppresses Experimental Autoimmune Encephalomyelitis

The ERK1/2 signaling pathway promotes myelin wrapping during development and remyelination, and sustained ERK1/2 activation in the oligodendrocyte (OL) lineage results in hypermyelination of the CNS. We therefore hypothesized that increased ERK1/2 signaling in the OL lineage would 1) protect against...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeffries, Marisa A., Obr, Alison E., Urbanek, Kelly, Fyffe-Maricich, Sharyl L., Wood, Teresa L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691909/
https://www.ncbi.nlm.nih.gov/pubmed/33228381
http://dx.doi.org/10.1177/1759091420971916
_version_ 1783614394898317312
author Jeffries, Marisa A.
Obr, Alison E.
Urbanek, Kelly
Fyffe-Maricich, Sharyl L.
Wood, Teresa L.
author_facet Jeffries, Marisa A.
Obr, Alison E.
Urbanek, Kelly
Fyffe-Maricich, Sharyl L.
Wood, Teresa L.
author_sort Jeffries, Marisa A.
collection PubMed
description The ERK1/2 signaling pathway promotes myelin wrapping during development and remyelination, and sustained ERK1/2 activation in the oligodendrocyte (OL) lineage results in hypermyelination of the CNS. We therefore hypothesized that increased ERK1/2 signaling in the OL lineage would 1) protect against immune-mediated demyelination due to increased baseline myelin thickness and/or 2) promote enhanced remyelination and thus functional recovery after experimental autoimmune encephalomyelitis (EAE) induction. Cnp-Cre;Mek1DD-eGFP/+ mice that express a constitutively active form of MEK1 (the upstream activator of ERK1/2) in the OL lineage, exhibited a significant decrease in EAE clinical severity compared to controls. However, experiments using tamoxifen-inducible Plp-Cre(ERT);Mek1DD-eGFP/+ or Pdgfrα-Cre(ERT);Mek1DD-eGFP mice revealed this was not solely due to a protective or reparative effect resulting from MEK1DD expression specifically in the OL lineage. Because EAE is an immune-mediated disease, we examined Cnp-Cre;Mek1DD-eGFP/+ splenic immune cells for recombination. Surprisingly, GFP(+) recombined CD19(+) B-cells, CD11b(+) monocytes, and CD3(+) T-cells were noted when Cre expression was driven by the Cnp promoter. While ERK1/2 signaling in monocytes and T-cells is associated with proinflammatory activation, fewer studies have examined ERK1/2 signaling in B-cell populations. After in vitro stimulation, MEK1DD-expressing B-cells exhibited a 3-fold increase in CD138(+) plasmablasts and a 5-fold increase in CD5(+)CD1d(hi) B-cells compared to controls. Stimulated MEK1DD-expressing B-cells also exhibited an upregulation of IL-10, known to suppress the initiation of EAE when produced by CD5(+)CD1d(hi) regulatory B-cells. Taken together, our data support the conclusion that sustained ERK1/2 activation in B-cells suppresses immune-mediated demyelination via increasing activation of regulatory B10 cells.
format Online
Article
Text
id pubmed-7691909
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-76919092020-12-04 Cnp Promoter-Driven Sustained ERK1/2 Activation Increases B-Cell Activation and Suppresses Experimental Autoimmune Encephalomyelitis Jeffries, Marisa A. Obr, Alison E. Urbanek, Kelly Fyffe-Maricich, Sharyl L. Wood, Teresa L. ASN Neuro Original Article The ERK1/2 signaling pathway promotes myelin wrapping during development and remyelination, and sustained ERK1/2 activation in the oligodendrocyte (OL) lineage results in hypermyelination of the CNS. We therefore hypothesized that increased ERK1/2 signaling in the OL lineage would 1) protect against immune-mediated demyelination due to increased baseline myelin thickness and/or 2) promote enhanced remyelination and thus functional recovery after experimental autoimmune encephalomyelitis (EAE) induction. Cnp-Cre;Mek1DD-eGFP/+ mice that express a constitutively active form of MEK1 (the upstream activator of ERK1/2) in the OL lineage, exhibited a significant decrease in EAE clinical severity compared to controls. However, experiments using tamoxifen-inducible Plp-Cre(ERT);Mek1DD-eGFP/+ or Pdgfrα-Cre(ERT);Mek1DD-eGFP mice revealed this was not solely due to a protective or reparative effect resulting from MEK1DD expression specifically in the OL lineage. Because EAE is an immune-mediated disease, we examined Cnp-Cre;Mek1DD-eGFP/+ splenic immune cells for recombination. Surprisingly, GFP(+) recombined CD19(+) B-cells, CD11b(+) monocytes, and CD3(+) T-cells were noted when Cre expression was driven by the Cnp promoter. While ERK1/2 signaling in monocytes and T-cells is associated with proinflammatory activation, fewer studies have examined ERK1/2 signaling in B-cell populations. After in vitro stimulation, MEK1DD-expressing B-cells exhibited a 3-fold increase in CD138(+) plasmablasts and a 5-fold increase in CD5(+)CD1d(hi) B-cells compared to controls. Stimulated MEK1DD-expressing B-cells also exhibited an upregulation of IL-10, known to suppress the initiation of EAE when produced by CD5(+)CD1d(hi) regulatory B-cells. Taken together, our data support the conclusion that sustained ERK1/2 activation in B-cells suppresses immune-mediated demyelination via increasing activation of regulatory B10 cells. SAGE Publications 2020-11-23 /pmc/articles/PMC7691909/ /pubmed/33228381 http://dx.doi.org/10.1177/1759091420971916 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Article
Jeffries, Marisa A.
Obr, Alison E.
Urbanek, Kelly
Fyffe-Maricich, Sharyl L.
Wood, Teresa L.
Cnp Promoter-Driven Sustained ERK1/2 Activation Increases B-Cell Activation and Suppresses Experimental Autoimmune Encephalomyelitis
title Cnp Promoter-Driven Sustained ERK1/2 Activation Increases B-Cell Activation and Suppresses Experimental Autoimmune Encephalomyelitis
title_full Cnp Promoter-Driven Sustained ERK1/2 Activation Increases B-Cell Activation and Suppresses Experimental Autoimmune Encephalomyelitis
title_fullStr Cnp Promoter-Driven Sustained ERK1/2 Activation Increases B-Cell Activation and Suppresses Experimental Autoimmune Encephalomyelitis
title_full_unstemmed Cnp Promoter-Driven Sustained ERK1/2 Activation Increases B-Cell Activation and Suppresses Experimental Autoimmune Encephalomyelitis
title_short Cnp Promoter-Driven Sustained ERK1/2 Activation Increases B-Cell Activation and Suppresses Experimental Autoimmune Encephalomyelitis
title_sort cnp promoter-driven sustained erk1/2 activation increases b-cell activation and suppresses experimental autoimmune encephalomyelitis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691909/
https://www.ncbi.nlm.nih.gov/pubmed/33228381
http://dx.doi.org/10.1177/1759091420971916
work_keys_str_mv AT jeffriesmarisaa cnppromoterdrivensustainederk12activationincreasesbcellactivationandsuppressesexperimentalautoimmuneencephalomyelitis
AT obralisone cnppromoterdrivensustainederk12activationincreasesbcellactivationandsuppressesexperimentalautoimmuneencephalomyelitis
AT urbanekkelly cnppromoterdrivensustainederk12activationincreasesbcellactivationandsuppressesexperimentalautoimmuneencephalomyelitis
AT fyffemaricichsharyll cnppromoterdrivensustainederk12activationincreasesbcellactivationandsuppressesexperimentalautoimmuneencephalomyelitis
AT woodteresal cnppromoterdrivensustainederk12activationincreasesbcellactivationandsuppressesexperimentalautoimmuneencephalomyelitis